After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Pinpointing who will and won’t get Alzheimer’s disease is tricky for doctors, but new research suggests it may soon get ...

What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

Recent research highlights carnosic acid, found in rosemary and sage, as a potential weapon against Alzheimer's. Scientists ...

The ability of peptides to construct specific secondary structures provides a useful function for biomaterial design that cannot be achieved with traditional organic molecules and polymers. Inhibition ...

After decades of research, the U.S. Food and Drug Administration (FDA) has approved a test that can detect the buildup of amyloid plaques in the brain—a key marker of Alzheimer’s disease, ...

The FDA expanded the uses of GE HealthCare’s Vizamyl imaging agent for highlighting the presence of beta amyloid proteins in the brain, with new green lights that enable more objective sc | The ...